WuXi AppTec Co., Ltd. (HKG:2359)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Chemical Business	29.05B	29.17B	28.85B	14.09B	9.59B
Chemical Business Growth	-0.41%	1.12%	104.79%	46.93%	-
Test Business	5.67B	5.96B	5.72B	4.53B	3.28B
Test Business Growth	-4.82%	4.18%	26.38%	38.03%	-
Biology Business	2.54B	2.55B	2.48B	1.99B	1.53B
Biology Business Growth	-0.34%	3.13%	24.69%	30.05%	-
Unallocated Other	650.71M	996.23M	33.61M	27.52M	22.10M
Unallocated Other Growth	-34.68%	2863.71%	22.14%	24.50%	4.17%
High-end therapy CTDMO business (Wu Xi ATU)	-	-	1.31B	1.03B	1.06B
High-end therapy CTDMO business (Wu Xi ATU) Growth	-	-	27.44%	-2.79%	-
Domestic New Drug Research and Development Service Unit (Wu Xi DDSU)	-	-	969.63M	1.25B	1.06B
Domestic New Drug Research and Development Service Unit (Wu Xi DDSU) Growth	-	-	-22.49%	17.47%	-71.62%
Total	37.92B	38.68B	39.35B	22.90B	16.54B
Total Growth	-1.97%	-1.72%	71.84%	38.50%	28.46%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
China	7.05B	-	-	-	-
Overseas	30.87B	-	-	-	-
Total	37.92B	-	-	-	-

Source: S&P Global Market Intelligence.